Table 1.

Antimicrobial susceptibility and molecular characterization of selected A. baumannii isolates from two tertiary hospitals in Lima, Peru

Strain	Source	MIC (mg/L)											PT	ST	aOXA	iOXA
		IP	MP	CAZ	FEP	CTX	AK	GM	COLa	TGC	CiP	LEV
3	INEN	>32	>32	>256	192	>32	48	>256	0.5	4	>32	>32	A	1	23	69
29	INEN	>32	>32	>256	256	>32	96	>256	1	4	>32	>32	A	1	23	69
33	INEN	>32	>32	>256	48	>32	32	2	0.5	4	>32	>32	B	79	253	65
54	HNAL	0.38	0.75	4	16	>32	96	3	1	2	>32	>32	C	79	—	65
21	INEN	>32	>32	128	16	>32	>256	>256	2	2	>32	>32	D	2	72	66
34	INEN	>32	>32	>256	24	>32	3	2	0.5	3	>32	>32	D	2	72	66
47	INEN	>32	>32	192	24	>32	>256	>256	0.5	3	>32	32	D	2	72	66
55	HNAL	>32	>32	192	24	>32	>256	>256	0.5	3	>32	>32	D	2	72	66
69	HNAL	>32	>32	>256	24	>32	>256	>256	0.5	2	>32	>32	D	2	72	66
79	HNAL	>32	>32	>256	24	>32	>256	>256	0.5	2	>32	>32	D	2	72	66
42	INEN	>32	>32	>256	24	>32	>256	>256	0.5	2	>32	>32	E	2	72	66
4	INEN	>32	>32	256	24	>32	16	>256	0.5	1.5	>32	>32	F	79	72	65
32	INEN	0.5	1	>256	24	>32	64	4	0.5	2	>32	32	F	79	—	65
56	HNAL	>32	>32	96	24	>32	32	256	1	1.5	>32	32	F	79	72	65
37	INEN	>32	>32	96	32	>32	16	0.38	1	0.25	>32	32	G	3	23	71
60	HNAL	>32	>32	96	64	>32	32	0.38	1	0.5	>32	>32	G	3	23	71
61	HNAL	>32	>32	>256	16	>32	48	>256	1	1	>32	>32	H	108	72	132
53	INEN	>32	>32	>256	32	>32	24	2	0.5	2	>32	24	I	79	253	65

MIC minimum inhibitory concentration, INEN Instituto Nacional de Enfermedades Neoplásicas, HNAL Hospital Nacional Arzobispo Loayza, IP imipenem, MP meropenem, CAZ ceftazidime, FEP cefepime, CTX cefotaxime, AK amikacin, GM gentamicin, COL colistin, TGC tigecycline, CiP ciprofloxacin, LEV levofloxacin, PT pulsotype, ST sequence type, aOXA acquired OXA-type, iOXA intrinsic OXA-type

^aColistin’s MIC was determined by broth microdilution